According to Perrigo, Alcon Labs has filed a patent infringement suit in the United States District Court for the Northern District of Texas after Perrigo filed an abbreviated new drug application (ANDA) for a generic version of Alcon's Patanase olopatadine hydrochloride nasal spray. The FDA approved Alcon's NDA for Patanase for the treatment of seasonal allergic … [Read more...] about Perrigo files an ANDA for a generic Patanase nasal spray; Alcon files suit
Business
Some acetylcysteine inhalation solution now available
According to the FDA, American Regent/Luitpold has now released several batches of acetylcysteine inhalation solution, including 10 ml vials of both 100 mg/ml and 200 mg/ml solutions and 30 ml vials of the 200 mg/ml solution. The company's facility in Shirley, NY was closed in April 2011 due to safety concerns. Two other manufacturers, Roxanne Laboratories and … [Read more...] about Some acetylcysteine inhalation solution now available
Fentanyl nasal spray now available in the US
Archimedes Pharma has officially launched its Lazanda fentanyl nasal spray for the treatment of breakthrough pain in adult cancer patients in the United States. Lazanda, the first fentanyl nasal spray available in the US, was approved by the FDA at the end of June 2011. In Europe, where the product is marketed as PecFent, the spray is available in a handful of … [Read more...] about Fentanyl nasal spray now available in the US
Azelon gets financing for osteoporosis nasal spray, adds to management team
Prospect Venture Partners, Lighthouse Capital Partners, and Covington Venture Fund will provide a total of $4.5 million in Series A financing to Azelon Pharmaceuticals, formerly Zelos Therapeutics, for continued clinical development of Azelon’s ZT-034 teriparatide nasal spray for the treatment of osteoporosis. Teriparatide is a parathyroid hormone analog and is … [Read more...] about Azelon gets financing for osteoporosis nasal spray, adds to management team
Teva UK launches generic HFA salmeterol MDI
Teva UK has announced the launch of a generic CFC-free salmeterol metered dose inhaler in the UK; the product is a suspension pMDI that delivers 25 mcg per actuation. The UK granted marketing authorization for the Neovent/Sereflo inhaler for the treatment of asthma and COPD to Neolab Limited in April 2011. Kim Innes, Teva UK Commercial Director, commented, "We are … [Read more...] about Teva UK launches generic HFA salmeterol MDI
Alexza teams with Grupo Ferrer on Staccato loxapine inhaler
Alexza Pharmaceuticals and Spanish pharmaceutical company Grupo Ferrer International have formed a partnership to register, distribute, and promote the Adasuve Staccato loxapine inhaler for the treatment of agitation in patients with schizophrenia or bipolar disorder in Europe, Commonwealth of Independent States countries, and Latin America. The deal includes a $10 … [Read more...] about Alexza teams with Grupo Ferrer on Staccato loxapine inhaler
BASF and Ineos join forces in Styrolution
Inhaler manufacturers who have been purchasing acrylonitrile butadiene styrene (ABS) for inhaler housings from either BASF or Ineos will now have a new supplier: Styrolution. Ineos's Lustran, Novodur, and Absolac brands and BASF's Terluran brand will be sold by the new company, a 50/50 joint venture of BASF and Ineos, which is headquartered in Frankfurt/Main, Germany, … [Read more...] about BASF and Ineos join forces in Styrolution
Mymetics reclaims intranasal flu vaccine that had been licensed to Solvay
Swiss vaccine developer Mymetics Corporation has reclaimed an intranasal influenza vaccine that it had licensed to Solvay prior to Solvay's acquisition by Abbott Laboratories. Solvay had conducted a Phase 1 trial that found the vaccine to be well tolerated and safe and had made a milestone payment to Mymetics before stopping work on the project. Mymetics CFO Ronald … [Read more...] about Mymetics reclaims intranasal flu vaccine that had been licensed to Solvay
Second nasal delivery device contract for Bespak
Only about a month after entering the nasal delivery device market, Bespak has announced a second contract for development of an intranasal device. The company says that "a major global manufacturer of generic medicines" has awarded Bespak a contract for both development of its Unidose nasal drug delivery device for an undisclosed application and for manufacturing and … [Read more...] about Second nasal delivery device contract for Bespak
PPD agrees to be acquired for $3.9 billion
The board of directors of contract research organization PPD has approved a $3.9 billion all cash deal which will take the company private after its acquisition by the Carlyle Group and Hellman & Friedman. PPD offers formulation development and analytical services for a wide variety of OINDPs, including DPIs, MDIs, inhalation solutions, and nasal aerosols. The deal, … [Read more...] about PPD agrees to be acquired for $3.9 billion